Salazosulfapyridine

柳氮磺吡啶

Report date: 2022/02/14 16:02:52
NME

Base Information

Drug NameSalazosulfapyridine
Drug Alias Name水杨酰偶氮磺胺吡啶Sulphasalazine柳氮磺胺吡啶Sulfasalazine柳酸偶氮磺胺吡啶 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene inhibitors
TargetsLeukotriene
Therapy Area/IndicationsSolid tumoursDiarrheaArrhythmogenic Right Ventricular Dysplasia +[12] 
Global Approved IndicationsCrohn DiseaseColitis, UlcerativeArthritis, Rheumatoid
Approved Indications in ChinaCrohn DiseaseColitis, UlcerativeArthritis, Rheumatoid
Original Approved Country/TerritoryUnited States
Original Approved Date1950/06/20
Country/TerritoryUnited StatesEgyptMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalCairo UniversityPfizer Inc +[7] 
Inactive CompaniesNational Cancer InstituteSun Yat-Sen University
Active IndicationsArrhythmogenic Right Ventricular DysplasiaObstetric Labor, PrematureLichen Planus, Oral +[9] 
Inactive IndicationsSolid tumoursDiarrheaSpondylitis, Ankylosing

Other Information

ATC CodeA07EC01
Related LinksWikipediaDrugBankKEGG